{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021185","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.232184+00:00","generated_at":"2026-06-02T15:54:21.312576+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cumberland Pharmaceuticals Q1 net loss $1.9M; revenue $8.5M","bullets":["Net revenue $8.5M; Kristalose $3.2M, Sancuso $1.8M, Vibativ $1.6M, Caldolor $1.5M.","Net loss $1.9M ($0.14/share); adjusted loss $0.6M ($0.05/share).","Cash $19M, total assets $82M, liabilities $54M, equity $27M.","Caldolor highlighted in NOPAIN Act; CMS decision pending for 2025 Medicare reimbursement.","Ifetroban enrollment underway for Idiopathic Pulmonary Fibrosis trial (128 patients)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021185","json":"https://secwatch.observer/filing/0001628280-24-021185.json","markdown":"https://secwatch.observer/filing/0001628280-24-021185.md","text":"https://secwatch.observer/filing/0001628280-24-021185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024021185/0001628280-24-021185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024021185/cpix-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T15:54:21.312576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cbc72b255023dfbfc637ff61e5aa46804e644a03","claim":"CUMBERLAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $8.5 million.","evidence_excerpt":"Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders’ equity. “It","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024021185/0001628280-24-021185-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$8.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}